Views
3 years ago

Cardiopatía isquémica - Capítulo 9

  • Text
  • Usodeanticoagulantes
  • Anticoagulantes
  • Costabel
  • Juanpablocostabel
  • Aumento
  • Genera
  • Rivaroxaban
  • Aspirina
  • Tratamiento
  • Eventos
  • Riesgo
  • Estudio
  • Sangrado
  • Pacientes
Uso racional de anticoagulantes y fibrinolíticos en cardiopatía isquémica. Juan Pablo Costabel

EM Ylarri //

EM Ylarri // Farmacología Cardiovascular. De la molécula al paciente. Cardiopatía isquémica. • Zaman AG, Helft G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000);199, 251–266. • Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials. John W. Circulation. 2005; 112: 3855-3867. • GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico. Lancet 1990; 336: 65-71. • ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339: 753-70. • Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for STelevation myocardial infarction: the international randomised open-label. ATOLL trial. Montalescot G, et al ATOLL Investigators. Lancet 2011;378(9792): 693–703. • Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344: e553. • Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295: 1519-30. • Eikelboom JW, Anand SS, Malmberg K. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936–194. • Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365: 699–708. • Eikelboom JW, Bosch J, Noly SJ, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. COMPASS Investigators. N Engl J Med 2017; 377: 1319-1330. • Annand SS and Yusuf S. Oral Anticoagulants in Patients With Coronary Artery Disease. J Am Coll Cardiol 2003; 41: 62S–69S. • Mega JL, Braunwald E, Wuiviott SD, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. ATLAS-ACS2-TIMI51 investigators. N Engl J Med 2012; 366: 9-19. • Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): A double-blind, multicentre, randomised trial. Ohman EM, et al. 2017 Lancet;389: 1799-2808. • Paikin JS, Wright DS, Couther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 2010; 121: 2067-2070. • Ekeloef S, Alamili M, Deveraux PJ, et al. Troponin elevations after non-cardiac, non-vascular surgery are predictive of major adverse cardiac events and mortality: a systematic review and meta-analysis. Br J Anaesth. 2016; 117: 559-568. • Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/ or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology working group on thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155–3179. • Infarto agudo de miocardio en la República Argentina. Registro CONAREC XVII. Gonzalo E. Perez, et al. Rev Argent Cardiol 2013;81: 390-399. • Relevamiento nacional permanente de enfermedades cardiovasculares para el monitoreo de políticas públicas. Estudio piloto de infarto agudo de miocardio con elevación del st (argen-iam-st). • Infarto agudo de miocardio con supradesnivel persistente del segmento ST. Registro multicéntrico SCAR (Síndromes Coronarios Agudos en Argentina) de la Sociedad Argentina de Cardiología. Mauro J. García Aurelio et al. Rev. argent. cardiol. vol.82 no.4 • Collen D and Lijnen HR. Molecular mechanisms of thrombolysis: implications for therapy. Biochem Pharmacol. 1990; 40: 177-186. 116

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015